Carmen Diez, Ph.D.
Carmen Diez, Ph.D., joined Nextech Invest Ltd as an investment analyst in 2018. Carmen, a scientist by training, is thrilled to be on the cutting edge of oncology therapies being developed worldwide. Prior to joining Nextech, Carmen worked as a private equity analyst at HBM Partners and is a former board observer of Turning Point Therapeutics (NASDAQ: TPTX). Carmen holds a B.S. in agronomic engineering with a specialization in biotechnology, a M.Sc. in medical biotechnology and a Ph.D. in biotechnology from Universidad Politécnica de Valencia, Spain. Carmen also completed a postdoctoral fellowship at University Children’s Hospital Zurich, where she specialized in the development of novel therapies for metabolic rare disorders and oncology.
From the snowy Alps to the sunny Valencian coast, Carmen enjoys outdoor sports all-year round.